Case-control analysis on metformin and cancer of the esophagus

Cancer Causes and Control

Volumn 24, Issue 10, 2013, Pages 1763-1770

  Becker, Claudia ^a   Meier, Christoph R ^a,b   Jick, Susan S ^b   Bodmer, Michael ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anti diabetic drugs; Case control analysis; Epidemiology; Esophageal cancer; Metformin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; PROTON PUMP INHIBITOR; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SMOKING; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; METFORMIN; MIDDLE AGED; RISK FACTORS;

EID: 84884594000     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0253-6     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Brown LM, Devesa SS, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100:1184-1187
3. Hansson LE, Sparen P, Nyren O (1993) Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 54:402-407
4. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP (2008) Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 103:2694-2699
5. Dikken JL, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, van Sandick JW, Cats A, Verheij M, Coebergh JW, van de Velde CJ (2012) Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 48:1624-1632
6. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241
7. Asia Pacific Cohort Studies Collaboration (2007) The burden of overweight and obesity in the Asia-Pacific region. Obes Rev 8:191-196
8. Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN (2008) Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8:200
9. Lam DW, LeRoith D (2012) The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 19:93-96
10. Lagergren J (2011) Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol 8:340-347
11. Ryan AM, Duong M, Healy L, Ryan SA, Parekh N, Reynolds JV, Power DG (2011) Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 35:309-319
12. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674-1685
13. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128:635-643
14. Neale RE, Doecke JD, Pandeya N, Sadeghi S, Green AC, Webb PM, Whiteman DC (2009) Australian Cancer S. Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br J Cancer 100:795-798
15. Jiang X, Bernstein L, Tseng CC, Wu AH (2012) Diabetes and risk of esophageal and gastric adenocarcinomas. Int J Cancer 131:1417-1422
16. Rubenstein JH, Davis J, Marrero JA, Inadomi JM (2005) Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther 22:267-271
17. Huang W, Ren H, Ben Q, Cai Q, Zhu W, Li Z (2012) Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. Cancer Causes Control 23:263-272
18. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7:e33411
19. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA (2012) Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23:991-1008
20. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451-1461
21. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9:1092-1099
22. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11:20
23. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM (2013) Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52:1002-1009
24. Kobayashi M, Kato K, Iwama H, Fujihara S, Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, Miyoshi H, Kobara H, Mori H, Murao K (2012) Masaki T. In vitro study. Int J Oncol, Antitumor effect of metformin in esophageal cancer
25. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646
26. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12:159-169
27. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273
28. Williams T, van Staa TP, Puri S, Eaton S (2012) Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource Ther Adv. Drug Saf 3:89-99
29. Wood L, Martinez C (2004) The general practice research database: role in pharmacovigilance. Drug Saf 27:871-881
30. Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097-1099
31. Jick SS, Kaye JA, Vasilakis-Scaramozza C (2003) Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy 23:686-689
32. Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:e128-e136
33. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4-14
34. Lubin JH, Cook MB, Pandeya N, Vaughan TL, Abnet CC, Giffen C, Webb PM, Murray LJ, Casson AG, Risch HA, Ye W, Kamangar F, Bernstein L, Sharp L, Nyren O, Gammon MD, Corley DA, Wu AH, Brown LM, Chow WH, Ward MH, Freedman ND, Whiteman DC (2012) The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol 36:306-316
35. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578
36. Steffen A, Schulze MB, Pischon T, Dietrich T, Molina E, Chirlaque MD, Barricarte A, Amiano P, Quiros JR, Tumino R, Mattiello A, Palli D, Vineis P, Agnoli C, Misirli G, Boffetta P, Kaaks R, Rohrmann S, Bueno-de-Mesquita HB, Peeters PH, May AM, Spencer EA, Allen NE, Bingham S, Tjonneland A, Halkjaer J, Overvad K, Stegger J, Manjer J, Lindkvist B, Hallmanns G, Stenling R, Lund E, Riboli E, Gonzalez CA, Boeing H (2009) Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 18:2079-2089
37. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657-663
38. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341:c4444
39. Walker AM (2011) Identification of esophageal cancer in the General Practice Research Database. Pharmacoepidemiol Drug Saf 20:1159-1167
40. Sharpe KH, McMahon AD, McClements P, Watling C, Brewster DH, Conway DI (2012) Socioeconomic inequalities in incidence of lung and upper aero-digestive tract cancer by age, tumour subtype and sex: a population-based study in Scotland (2000-2007). Cancer Epidemiol 36:e164-e170